Abstract
The present disclosure provides a method of reversing ticagrelor-associated bleeding in a patient by administering an antibody or fragment thereof that binds to ticagrelor.
Full Text
What is claimed is:
The present disclosure provides a method of reversing ticagrelor-associated bleeding in a patient by administering an antibody or fragment thereof that binds to ticagrelor.
Timeline
Filed
04/01/2026Published
07/23/2026Granted
Not AvailableIPC Codes(4)
C07K 16/44:against material not provided for elsewhere
A61K 39/00:Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N 33/53)
A61P 7/04:Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents